[Author Disclosure: This content reflects the views of the author and is provided for informational purposes only. It does not constitute investment advice and is not a recommendation or endorsement by BioTech Funding Portal. Any investment decision should be based solely on the issuer’s official offering materials.]
Pre-IND is a specific moment, and it doesn't last.
Right now, before Glafabra's IND is filed, is when Japan licensing terms, partnership structures, and — for this crowdfunding round — investment interest can be shaped at the earliest, most favorable stage of the company's life. Once a U.S. cohort is enrolling, the terms of every conversation change.
This isn't urgency for its own sake. It's just where we are in the timeline, and we think it's worth naming plainly.
If you've registered interest already: what made the timing matter to you? If you haven't yet, what's holding you back?
Follow the whole series: https://bit.ly/Glafabra-TTW
@Brian Christie @Neva West @Chris Hopkins @Tetsu Yung
Testing the Waters disclosure: We are considering a capital raise and are "Testing the Waters" under Regulation Crowdfunding. No money or other consideration is being solicited, and any that is sent in response will not be accepted. We cannot accept any offer to buy securities, and no part of the purchase price can be received until an offering statement is filed and only through the BioTech Funding Portal platform. Any indication of interest is non-binding and involves no obligation or commitment of any kind.
Register for FREE to comment or continue reading this article. Already registered? Login here.
0